The article, authored by Ashley D. Kendall of the University of Illinois Chicago, Noah Robinson of XRHealth USA, Robin J. Mermelstein of the University of Illinois Chicago, and Steven D. Hollon of Vanderbilt University, makes a deceptively simple point with far-reaching consequences. When a mental health app is tested against a treatment control — a comparison condition that itself contains some active therapeutic ingredient, such as psychoeducation, mood tracking, relaxation exercises or generic support — the trial is not measuring whether the app works. It is measuring whether the app works better than another intervention that may already deliver a meaningful share of the benefit. A null result in that context is not evidence of treatment failure. It may simply be evidence that two modestly effective treatments are, on average, equally effective.

The authors ground this argument in decades of psychotherapy research, a literature that digital mental health has often ignored when importing the randomized controlled trial as its gold standard. Landmark studies in face-to-face therapy, including the widely cited 2010 JAMA analysis by Fournier and colleagues on antidepressant medication and psychotherapy, established long ago that the difference between an active treatment and a credible control tends to shrink as controls become more structurally similar to treatments. Meta-analytic work by Cuijpers and colleagues on psychotherapy for depression reached the same conclusion: the choice of control condition can swing effect sizes dramatically, and pill placebos, psychological placebos and waitlists produce systematically different estimates of how well a therapy works. In other words, the problem Kendall and her colleagues describe is not unique to apps. It is an old and well-understood feature of clinical trials design that the app field has largely failed to absorb.

The technical logic is straightforward. A treatment control in a mental health app trial is not inert. It typically involves contact with researchers, expectation of benefit, structured engagement with content derived from therapeutic principles, and regular self-monitoring — all of which are known to produce symptom improvement on their own. When the active app and the control app both reduce symptoms by a comparable amount, the trial’s statistical machinery reports no significant difference. But the absolute benefit experienced by participants in both arms may be substantial. Reporting that result as a treatment failure conflates comparative advantage with clinical efficacy, two entirely different questions. The first asks whether the app beats a competitor; the second asks whether it helps people relative to no treatment at all. Treatment controls are designed to answer the first question, yet their results are routinely interpreted as answers to the second.

This interpretive habit has real-world costs. Apps that fail to beat treatment controls may be deprioritized by funders, rejected by regulators, passed over by health systems and dismissed by clinicians, even when the trials show that users improved meaningfully. Meanwhile, the enormous unmet need in mental health care — driven by workforce shortages, cost barriers and geographic inequity — means that even modestly effective scalable tools could deliver enormous public health value. The Comment argues that holding apps to a standard of superiority over other active interventions is a standard that many established, widely reimbursed psychotherapies would themselves struggle to meet, particularly against well-constructed psychological placebos. Chambless and Hollon’s influential 1998 framework for establishing empirically supported treatments recognized this problem nearly thirty years ago, emphasizing that efficacy must be demonstrated against appropriate comparison conditions and that equivalence to an established treatment can itself constitute evidence of effectiveness.

The authors also point to a related distortion: expectation effects and common factors. Any intervention that engages a person in a structured effort to feel better recruits hope, motivation, self-efficacy and the therapeutic alliance in diluted form. These ingredients are not noise to be controlled away; they are part of why psychological treatments work. A treatment control deliberately packages many of them. When both arms of a trial contain them, the measured difference between arms reflects only the incremental contribution of the app’s specific content over and above a foundation of generic benefit. For interventions whose mechanisms overlap heavily with those of their controls — as is often the case for apps built on behavioral activation, cognitive restructuring or mindfulness — small incremental effects are close to a statistical inevitability, not a signal of clinical worthlessness.

What, then, should the field do instead? The Comment calls for a diversification of trial designs rather than an abandonment of rigor. Single-case experimental designs, in which each participant serves as their own control across staggered phases of exposure to the intervention, can isolate within-person change with far fewer participants and are well suited to digital platforms that can randomize in real time. Sequential multiple assignment randomized trials, described in recent methodological reviews by Collins and colleagues, allow researchers to evaluate adaptive interventions in which the app’s content changes in response to a user’s progress. Hybrid effectiveness-implementation designs, formalized by Curran and colleagues, evaluate both whether an intervention works and how it functions in real-world care settings, providing information that traditional efficacy trials systematically omit. Dismantling and additive designs can determine which components of an app contribute to benefit, rather than asking only whether the whole package beats a competitor.

The authors also emphasize the value of alternative control strategies borrowed from other areas of medicine. Work by Mulla, Guyatt and colleagues on the interpretation of trials against active comparators shows that non-inferiority and equivalence designs, properly powered and pre-specified, can establish that a new treatment preserves most of the benefit of an existing one while offering advantages in cost, access or tolerability. For mental health apps, whose defining advantages are scalability and low marginal cost, demonstrating equivalence to clinician-delivered care in a non-inferiority framework may be a far more informative and honest question than chasing small superiority effects against enriched controls. Furukawa and colleagues’ work on minimally important differences provides the statistical scaffolding: what matters clinically is not whether a p-value crosses a threshold, but whether the difference between arms — or the improvement within an arm — exceeds the smallest change patients would consider meaningful.

The timing of this intervention matters. The digital mental health sector has matured rapidly, with recent syntheses by Torous and colleagues in World Psychiatry and by Linardon and colleagues mapping a crowded landscape of apps, growing regulatory attention and persistent uncertainty about which products deserve clinical endorsement. A 2022 analysis by Goldberg and colleagues found that while app-based interventions show pooled benefits for depression and anxiety, effects measured against active controls were markedly smaller than those measured against waitlists — precisely the pattern the new Comment predicts. As health systems begin to prescribe apps and payers consider reimbursement, getting the evaluation framework right is no longer an academic quibble. Misreading null superiority results could throttle the pipeline of accessible care just when demand for it has never been higher.

None of this means the authors are asking for a lower bar. They are asking for a more precise one. An app that helps users improve but does no better than a thoughtful control deserves scrutiny of its mechanisms, its engagement design and its incremental value — not a blanket verdict of failure. Conversely, the framework they propose would still condemn apps that produce no meaningful improvement at all, and non-inferiority and single-case designs are arguably more demanding than the status quo, requiring explicit specification of what counts as a clinically meaningful change. The core message is statistical as much as clinical: a null difference between two active treatments is an uninformative result about efficacy, and decades of psychotherapy research already knew it. Digital mental health, the Comment suggests, will only fulfill its promise once its trials start asking the questions its technology can actually answer.

Subject of Research: Evaluation methodology for mental health app clinical trials

Article Title: Failure to outperform treatment controls does not imply treatment failure for mental health apps

Article References: Failure to outperform treatment controls does not imply treatment failure for mental health apps. (n.d.). https://doi.org/10.1038/s44220-026-00715-4

Image Credits: AI Generated

DOI: 10.1038/s44220-026-00715-4

Keywords: mental health apps, digital mental health, treatment controls, randomized controlled trials, clinical trial design, psychotherapy research, non-inferiority trials, effect sizes, Nature Mental Health, outcomes research, implementation science, depression and anxiety

The concept at the center of the framework is known as stress generation. Unlike stressors that occur independently of a person’s actions, stress-generating events are at least partly shaped by an individual’s behaviour, relationships or decisions. Examples might include escalating an argument, withdrawing from social contact, failing to meet an obligation because of low motivation, or repeatedly seeking reassurance in ways that strain relationships. The researchers emphasize that this process is not deliberate and should not be interpreted as blaming people for their suffering. Instead, stress generation describes a dynamic interaction between symptoms and the social environment, in which psychological difficulties can alter behaviour and those behavioural changes can produce new sources of stress.

The proposed model begins with changes in affective functioning, the systems involved in emotional experience and regulation. Internalizing disorders are commonly associated with heightened negative affect, reduced positive affect, emotional reactivity and difficulty returning to an emotional baseline after distress. A person may become more sensitive to rejection, more easily overwhelmed by ordinary setbacks or less able to experience reward from social and daily activities. These affective alterations can influence how situations are interpreted and how quickly a person responds to them. A minor disagreement, for example, may feel unusually threatening, while a neutral message from a friend may be experienced as evidence of disapproval. Over time, such emotional shifts can shape patterns of action that affect relationships, work and other areas of life.

The next stage involves everyday behaviour. When people are experiencing persistent sadness, fear, irritability or emotional exhaustion, they may avoid demanding situations, reduce communication, postpone responsibilities or respond more intensely during interpersonal conflict. These behaviours can provide short-term relief. Avoiding a difficult conversation may temporarily reduce anxiety, and withdrawing from social contact may protect someone from immediate embarrassment or perceived rejection. However, the same strategies can create longer-term consequences, including missed deadlines, financial complications, social isolation or resentment from family members and colleagues. In this way, behaviour that is understandable in the moment can unintentionally increase the probability of future stress.

The model gives particular importance to cognitive vulnerability, which can determine whether an emotional or behavioural reaction remains contained or develops into a larger chain of events. Cognitive vulnerability includes persistent patterns such as negative interpretations, rumination, hopeless expectations and beliefs that stressful outcomes are inevitable. Rumination can keep attention fixed on a conflict long after it has ended, while threat-focused thinking can encourage defensive or avoidant responses. When these cognitive processes interact with strong negative emotion, a person may repeatedly revisit the same event, interpret ambiguous actions in the most damaging way and respond as though a feared outcome has already occurred. That response may then provoke real interpersonal difficulties, providing apparent confirmation of the original belief.

This sequence can create a feedback loop between the individual and the surrounding social environment. An emotionally distressed person may withdraw, communicate less clearly or react defensively. Other people may respond with frustration, criticism or reduced support. The individual can then perceive those reactions as further evidence of rejection or hostility, increasing emotional distress and making additional problematic behaviour more likely. The process is not necessarily confined to one relationship or one type of stressor. Repeated cycles may spread across friendships, family interactions, romantic relationships, academic settings and workplaces. As stress accumulates, the resulting burden may worsen symptoms, creating the conditions for another round of stress generation.

The researchers describe this process as transdiagnostic, meaning that it may operate across multiple internalizing conditions rather than belonging to a single diagnosis. Depression, generalized anxiety, social anxiety and related forms of psychopathology often differ in their specific symptoms, but they can share underlying features such as negative affect, avoidance, interpersonal sensitivity and repetitive negative thinking. These common factors may help explain why stress generation is linked to impairment across diagnostic categories. Instead of treating each disorder as an isolated cause of stress, the framework maps how shared emotional, behavioural and cognitive mechanisms can produce similar patterns of escalating difficulty in different people.

A major implication of the model is that stress generation should not be viewed as a single event with a single cause. It is better understood as a process unfolding over time. Affective disruption may increase the likelihood of a particular behaviour, the behaviour may alter the social environment, and the resulting consequences may activate cognitive vulnerabilities that intensify emotional symptoms. The timing and sequence of these steps are important. A brief episode of avoidance may have little effect in one context but lead to substantial stress when it occurs repeatedly, affects an important responsibility or is interpreted by others as indifference. This process-based perspective may help researchers identify which links in the chain are most influential for different individuals.

The framework also points to several possible intervention targets. Treatment could focus directly on emotional regulation, helping people reduce reactivity and recover more effectively after distress. Behavioural approaches could address avoidance, withdrawal, disrupted routines and communication patterns that increase the likelihood of conflict or missed obligations. Cognitive interventions could target rumination, catastrophic interpretations and rigid expectations about rejection or failure. Because the model describes a reciprocal relationship between individuals and their environments, interventions might also include interpersonal strategies designed to repair damaged relationships, increase constructive communication and strengthen access to social support. Interrupting even one part of the cycle could potentially prevent later stressors from developing.

The Perspective does not present stress generation as an unavoidable consequence of internalizing psychopathology, nor does it suggest that individuals are responsible for every stressful event they experience. Rather, it offers a mechanistic account of how symptoms and circumstances can influence one another, sometimes producing self-reinforcing patterns that prolong illness and increase impairment. By bringing affective, behavioural and cognitive processes into a single framework, the model may help explain why some people recover after a stressful episode while others enter a cycle of accumulating difficulties. It also shifts attention toward prevention: identifying early changes in emotion, behaviour or thinking could make it possible to intervene before ordinary problems escalate into major life stress. For a field increasingly focused on personalized and transdiagnostic treatment, understanding how stress is generated may become a crucial step toward breaking the feedback loops that keep internalizing disorders alive.

Subject of Research: Stress generation processes in internalizing disorders

Article Title: A process model of stress generation in internalizing disorders

Article References: Starr, L.R., Dozois, D.J.A., Rnic, K. et al. A process model of stress generation in internalizing disorders. Nature Reviews Psychology (2026). https://doi.org/10.1038/s44159-026-00607-5

Image Credits: AI Generated

DOI: 10.1038/s44159-026-00607-5

Keywords: stress generation, internalizing disorders, depression, anxiety, affective functioning, cognitive vulnerability, behavioural processes, rumination, interpersonal stress, mental health interventions

The insulin index is a measure of how much a certain food raises insulin levels in the blood relative to a reference food, typically white bread. Unlike the glycemic index, which focuses solely on blood glucose response, the insulin index captures the broader pancreatic response, reflecting the complex hormonal milieu triggered by nutrient ingestion. In recent years, insulin’s role beyond glucose metabolism—especially its influence on the central nervous system—has come under increasing scrutiny. Insulin receptors are widely distributed in the brain, and insulin signaling pathways modulate neurotransmitter activity, neuroinflammation, and synaptic plasticity, all of which are integral to mood regulation and cognitive function.

The present study, conducted on a cohort of physically active Iranian adults, utilized detailed dietary assessments combined with validated psychological questionnaires to establish a robust data set. This group’s choice was deliberate, factoring in physical activity as a confounder, which is known to affect both insulin sensitivity and mental health outcomes. The researchers meticulously calculated each participant’s dietary insulin index scores based on their reported food intake over an extended period, and correlated these scores with metrics assessing depression, anxiety, and sleep quality.

One of the central revelations of this research is the association between high dietary insulin index scores and increased levels of depressive symptoms. This finding bridges metabolic dysregulation with mood disorders, supporting emerging hypotheses that insulin resistance and hyperinsulinemia contribute to neuropsychiatric pathologies. The mechanisms potentially involve insulin-mediated regulation of neurotransmitter systems such as serotonin and dopamine, which are critical in mood stabilization and reward processing. Elevated insulin response from certain foods might exacerbate neuroinflammation and oxidative stress, which are increasingly recognized as pathological contributors in depression.

Moreover, the study identifies a significant link between the dietary insulin index and anxiety disorders. Anxiety, a condition characterized by dysregulated fear and stress responses, has been linked to alterations in hypothalamic-pituitary-adrenal (HPA) axis function and sympathetic nervous system activity. Insulin’s role in modulating these systems implies that dietary factors triggering heightened insulin release may predispose individuals to anxiety symptoms. The research suggests that the consumption of foods with a high insulin index could potentiate cortisol release and amplify systemic inflammatory markers, thereby fueling anxiety pathophysiology.

Sleep disturbances, another focal point of the investigation, were also found to correlate strongly with dietary insulin index values. Sleep quality is fundamental for overall mental health, and disruptions in sleep architecture often precede or exacerbate psychiatric illnesses. The interplay between insulin signaling and circadian regulation is complex and involves central and peripheral clocks. Insulin influences the expression of clock genes and may affect melatonin production indirectly. The study highlights that diets provoking excessive insulin secretion could interfere with normal sleep patterns, possibly by altering glucose metabolism in brain regions controlling sleep-wake cycles.

The integration of this multifaceted approach—to consider diet, mental health, and physical activity simultaneously—marks a significant advancement in nutritional psychiatry. By controlling for physical activity, the researchers strengthened the causal inference between dietary insulin index and mental health outcomes. Physical activity, known for improving insulin sensitivity and neuroplasticity, was accounted for, underscoring that the dietary insulin response independently impacts psychological well-being.

Importantly, the Iranian context of this study adds a valuable geographical and cultural dimension to the literature. Dietary habits vary significantly across populations, and metabolic responses can be influenced by genetic, environmental, and lifestyle factors. Studying a physically active sample in Iran offers insights that might differ from Western cohorts traditionally researched in this domain. It sets the stage for cross-cultural comparisons and tailored dietary recommendations that consider population-specific metabolic profiles.

The study’s methodological rigor deserves attention as well. Utilizing validated dietary insulin index tables, coupled with standardized psychological assessments such as the Beck Depression Inventory and the Pittsburgh Sleep Quality Index, the researchers ensured high validity and reliability in their data collection. Statistical analyses controlled for confounders including age, sex, BMI, and socioeconomic status, enhancing the robustness of their conclusions. This comprehensive approach underscores the intricate links between diet-induced insulin dynamics and psychological health metrics.

From a clinical perspective, these findings raise important questions about the role of diet modification as a non-pharmacological intervention in mental health management. If dietary insulin index influences depressive and anxiety symptoms, then personalized nutrition plans aimed at mitigating insulin spikes could complement traditional therapeutic strategies. Such interventions hold promise for improving sleep quality, reducing anxiety burden, and alleviating depressive episodes through metabolic modulation rather than solely relying on psychotropic medication.

Moreover, the implications for public health policy are profound. Given the rising prevalence of mood disorders and sleep disturbances globally, identifying modifiable dietary factors offers a cost-effective avenue for prevention and management. Public health strategies that promote foods with lower insulin indices, alongside encouraging physical activity, could become central pillars in combating the mental health epidemic.

The neurobiological explanations posited by the researchers suggest a fertile ground for future investigations. These include exploring the insulin signaling cascade in different brain regions implicated in mood and arousal regulation, investigating genetic polymorphisms affecting insulin receptor sensitivity, and assessing the longitudinal impact of insulin-modulating diets on mental health trajectories. Advanced neuroimaging and biomarker analytics could elucidate the direct neural correlates of dietary insulin fluctuations.

Despite the strengths, the study acknowledges limitations such as its observational design, which precludes definitive causal inferences. The reliance on self-reported dietary data introduces potential recall bias, and unmeasured lifestyle factors might confound the observed associations. Nevertheless, the findings provide a compelling rationale for controlled interventional studies to validate causality.

In conclusion, this pioneering research illuminates the nuanced relationship between dietary insulin responses and mental health outcomes in physically active adults. It complements a growing body of evidence positioning metabolic health as a cornerstone of psychological well-being. As the field of nutritional psychiatry evolves, the dietary insulin index emerges as a critical metric warranting integration into clinical assessments and personalized nutrition strategies aimed at improving mental health outcomes. This study is a clarion call for a multidisciplinary approach encompassing endocrinology, psychiatry, nutrition, and public health to tackle the complex challenges posed by mood and sleep disorders in contemporary society.

Subject of Research:
Association between dietary insulin index and risk of depression, anxiety, and sleep disturbance in physically active adults.

Article Title:
Association between dietary insulin index and risk of depression, anxiety, and sleep disturbance in a group of Iranian physically active adults.

Article References:
Fazl, M.R., Haghighat Lari, M.M., Khoddami, M. et al. Association between dietary insulin index and risk of depression, anxiety, and sleep disturbance in a group of Iranian physically active adults. BMC Psychol 13, 715 (2025). https://doi.org/10.1186/s40359-025-03056-6

Image Credits: AI Generated

The investigation into the long-term effects of pediatric obesity interventions comprises a robust cohort of over 6,700 individuals. Each participant had received treatment for obesity during their childhood, identified through the BORIS register, which is the Swedish Childhood Obesity Treatment Register. The researchers followed the subjects into young adulthood, utilizing an impressive array of national health databases, including the Swedish Patient Register, the Prescribed Drugs Register, and the Cause of Death Register. Furthermore, a control group from the general population, matched by age, sex, and residence, enriches the findings and allows for robust comparisons.

The obesity treatment program analyzed in this research focused on “behavioral lifestyle therapy.” This approach includes comprehensive support for children and their families to foster healthy dietary habits, increase physical activity, and improve sleep patterns. Despite the challenges associated with maintaining weight loss, the outcomes indicate that effective intervention during childhood can alleviate the burden of obesity-related diseases. Those who respond well to treatment show a significantly reduced risk for severe health problems such as type 2 diabetes, hypertension, and dyslipidemia as they transition into adulthood.

Despite these promising results regarding physical health, the study reveals a concerning aspect of mental health. Surprisingly, even among children who successfully lose weight through treatment, the risk of developing anxiety and depression in young adulthood remains unchanged. This finding challenges long-held beliefs that weight loss would positively influence mental health. Dr. Emilia Hagman, the lead researcher and an esteemed faculty member at the Department of Clinical Science, Intervention and Technology at Karolinska Institutet, articulates this disappointment, noting, “It has been believed that weight loss could decrease symptoms of depression and anxiety, but we can now show that it’s not the case.”

The implications of these findings highlight a critical need for parallel treatment strategies to address both the physical and psychological challenges faced by children with obesity. With mental health issues persisting despite physical health improvements, healthcare providers must consider integrated approaches to improve overall well-being. Dr. Hagman emphasizes the importance of early intervention, noting that timely treatment not only enhances physical health outcomes but also helps mitigate associated long-term risks.

In addition to traditional lifestyle therapy, recent advancements in pharmaceutical options warrant exploration. Although the study did not include GLP-1 analogues, a class of medications that have gained traction in the obesity treatment landscape, Dr. Hagman acknowledges their potential benefits. These medications, which help curb hunger, could offer a complementary avenue to traditional behavioral therapies, especially for children struggling to manage their appetite effectively. Nevertheless, she stresses that lifestyle intervention remains the cornerstone of treating childhood obesity.

The research sets the stage for future inquiries into more tailored therapies by identifying which interventions might be most beneficial for varying individuals. In an era where personalized medicine is becoming the gold standard, understanding the unique health markers that contribute to long-term success in obesity treatment is paramount. Future studies will undoubtedly build on this foundation to enhance therapeutic outcomes in both physical and mental health domains.

As childhood obesity continues to pose a significant public health challenge across the globe, the findings of this study offer a timely reminder of the complex interplay between physical health and mental well-being. While treating childhood obesity effectively can reduce immediate health risks, the persistent prevalence of anxiety and depression underscores the need for comprehensive approaches. By integrating physical health initiatives with mental health support, health practitioners can strive for a more holistic approach toward improving the lives of children with obesity.

Ultimately, this study serves to galvanize attention on critical mental health challenges that persist alongside physical treatment gains. The results reflect the pressing need for continuous research and advocacy in addressing not only the physical manifestations of childhood obesity but also the emotional scars that can linger as young individuals navigate their formative years and transition into adulthood. As the scientific community delves deeper into these findings, a renewed commitment to dual-focused treatment strategies offers hope for enhancing the overall quality of life for those affected by childhood obesity.

Given the concerning statistics and ongoing health ramifications, it is imperative that we mobilize resources, knowledge, and support for interventions targeting both weight management and mental health among children. The intersection of these two spheres will dictate not only the trajectory of individual lives but also the health landscape of future generations.

Subject of Research:
People

Article Title:
Effect of Pediatric Obesity Treatment on Long-Term Health

News Publication Date:
21-Jan-2025

Web References:
https://doi.org/10.1001/jamapediatrics.2024.5552

References:
(Information not provided in the original content)

Image Credits:
(Information not provided in the original content)

Keywords:
Childhood obesity, Depression, Anxiety, Type 2 diabetes, Hypertension, Public health, Pediatric obesity treatment, Behavioral lifestyle therapy